G1 Therapeutics Inc (GTHX) VP Sells $31,035.00 in Stock

G1 Therapeutics Inc (NASDAQ:GTHX) VP Jennifer K. Moses sold 750 shares of the firm’s stock in a transaction dated Monday, November 5th. The shares were sold at an average price of $41.38, for a total value of $31,035.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of G1 Therapeutics stock opened at $45.67 on Friday. The stock has a market cap of $1.44 billion, a PE ratio of -12.79 and a beta of 1.16. G1 Therapeutics Inc has a 12 month low of $18.03 and a 12 month high of $69.57.

G1 Therapeutics (NASDAQ:GTHX) last announced its quarterly earnings data on Wednesday, November 7th. The company reported ($0.59) EPS for the quarter, beating the consensus estimate of ($0.67) by $0.08. On average, sell-side analysts anticipate that G1 Therapeutics Inc will post -2.64 earnings per share for the current fiscal year.

Several research firms have weighed in on GTHX. Needham & Company LLC lowered their price target on G1 Therapeutics from $76.00 to $74.00 and set a “buy” rating on the stock in a report on Thursday. BidaskClub raised G1 Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $79.00 price target on shares of G1 Therapeutics in a report on Monday, September 17th. BTIG Research began coverage on G1 Therapeutics in a report on Monday, September 10th. They issued a “buy” rating and a $80.00 price target on the stock. Finally, JPMorgan Chase & Co. raised their price target on G1 Therapeutics from $58.00 to $63.00 and gave the company an “overweight” rating in a report on Friday, August 10th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $74.00.

Several institutional investors have recently made changes to their positions in GTHX. Northern Trust Corp increased its position in shares of G1 Therapeutics by 87.8% during the 1st quarter. Northern Trust Corp now owns 156,437 shares of the company’s stock valued at $5,796,000 after purchasing an additional 73,149 shares during the last quarter. BlackRock Inc. increased its position in shares of G1 Therapeutics by 71.9% during the 1st quarter. BlackRock Inc. now owns 1,281,060 shares of the company’s stock valued at $47,463,000 after purchasing an additional 535,615 shares during the last quarter. BNP Paribas Arbitrage SA increased its position in shares of G1 Therapeutics by 58.4% during the 1st quarter. BNP Paribas Arbitrage SA now owns 2,835 shares of the company’s stock valued at $105,000 after purchasing an additional 1,045 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in shares of G1 Therapeutics by 54.9% during the 1st quarter. The Manufacturers Life Insurance Company now owns 10,800 shares of the company’s stock valued at $401,000 after purchasing an additional 3,826 shares during the last quarter. Finally, Ladenburg Thalmann Financial Services Inc. increased its position in shares of G1 Therapeutics by 44.4% during the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,900 shares of the company’s stock valued at $144,000 after purchasing an additional 1,200 shares during the last quarter. Hedge funds and other institutional investors own 69.09% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “G1 Therapeutics Inc (GTHX) VP Sells $31,035.00 in Stock” was originally posted by Stock Observer and is the property of of Stock Observer. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this report can be read at https://www.thestockobserver.com/2018/11/10/g1-therapeutics-inc-gthx-vp-sells-31035-00-in-stock.html.

G1 Therapeutics Company Profile

G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development.

Featured Article: Hedge Funds – How They Work For Investors

Insider Buying and Selling by Quarter for G1 Therapeutics (NASDAQ:GTHX)

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply